PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3)

Carcinogenesis

Volumn 31, Issue 3, 2010, Pages 455-461

  Dossus, Laure ^a   Kaaks, Rudolf ^a   Canzian, Federico ^a   Albanes, Demetrius ^b   Berndt, Sonja I ^b   Boeing, Heiner ^c   Buring, Julie ^d   Chanock, Stephen J ^b   Clavel Chapelon, Francoise ^e   Feigelson, Heather Spencer ^f,g   Gaziano, John M ^d   Giovannucci, Edward ^d,h   Gonzalez, Carlos ⁱ   Haiman, Christopher A ^j   Hallmans, Göran ^k   Hankinson, Susan E ^d   Hayes, Richard B ^c,l   Henderson, Brian E ^j   Hoover, Robert N ^b   Hunter, David J ^h   Khaw, Kay Tee ^m   Kolonel, Laurence N ⁿ   Kraft, Peter ^h   Ma, Jing ^d   Le Marchand, Loic ^m   Lund, Eiliv ^o   Peeters, Petra H M ^p   Stampfer, Meir ^d,h   Stram, Dan O ^j   Thomas, Gilles ^c,e   Thun, Michael J ^f   Tjonneland, Anne ^q   Trichopoulos, Dimitrios ^h,r   Tumino, Rosario ^s   Riboli, Elio ^t   Virtamo, Jarmo ^u   Weinstein, Stephanie J ^b   Yeager, Meredith ^c,v   Ziegler, Regina G ^b   Cox, David G ^e   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e INSERM   (France)

^f AMERICAN CANCER SOCIETY   (United States)

^g KAISER PERMANENTE   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UMEÅ UNIVERSITY   (Sweden)

^l NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^o UNIVERSITY OF TROMSØ   (Norway)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^r HELLENIC HEALTH FOUNDATION   (Greece)

^s Cancer Registry Azienda   (Italy)

^t IMPERIAL COLLEGE LONDON   (United Kingdom)

^u NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^v SAIC FREDERICK INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 6; IL6 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ADULT; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; BREAST TUMOR; CASE CONTROL STUDY; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; ETHNIC GROUP; EUROPE; GENETIC PREDISPOSITION; GENETICS; INFLAMMATION; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RISK; STATISTICS; UNITED STATES;

ADENOCARCINOMA; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; CYCLOOXYGENASE 2; ETHNIC GROUPS; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK; UNITED STATES;

EID: 77950886696     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp307     Document Type: Article

References (55)

1. Coussens, L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
2. Nelson, W.G. et al. (2003) Prostate cancer. N. Engl. J. Med., 349, 366-381.
3. De Marzo, A.M. et al. (2007) Inflammation in prostate carcinogenesis. Nat. Rev. Cancer, 7, 256-269.
4. DeNardo, D.G. et al. (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res., 9, 212.
5. Lithgow, D. et al. (2005) Chronic inflammation and breast pathology: a theoretical model. Biol. Res. Nurs., 7, 118-129.
6. Vasto, S. et al. (2008) Inflammation and prostate cancer. Future Oncol., 4, 637-645.
7. Dennis, L.K. et al. (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology, 13, 72-79.
8. Gabay, C. (2006) Interleukin-6 and chronic inflammation. Arthritis Res. Ther., 8 (suppl. 2), S3.
9. Culig, Z. et al. (2005) Interleukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem., 95, 497-505.
10. Hong, D.S. et al. (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer, 110, 1911-1928.
11. Dai, Y. et al. (2006) Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J. Gastroenterol., 12, 2884-2889.
12. Rayyan, Y. et al. (2002) The role of NSAIDs in the prevention of colon cancer. Cancer Invest., 20, 1002-1011.
13. Schildkraut, J.M. et al. (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology, 17, 104-107.
14. Harris, R.E. et al. (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology, 7, 203-205.
15. Jacobs, E.J. et al. (2005) A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl Cancer Inst., 97, 975-980.
16. Howe, L.R. (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res., 9, 210.
17. Hussain, T. et al. (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett., 191, 125-135.
18. Gao, J. et al. (2007) Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J. Toxicol. Environ. Health A, 70, 908-915.
19. Cox, D.G. et al. (2007) A polymorphism in the 3# untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res., 9, R3.
20. Langsenlehner, U. et al. (2006) The cyclooxygenase-2 (PTGS2) 8473T.C polymorphism is associated with breast cancer risk. Clin. Cancer Res., 12, 1392-1394.
21. Cheng, I. et al. (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer, 97, 557-561.
22. Danforth, K.N. et al. (2008) Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis, 29, 568-572.
23. Shahedi, K. et al. (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer, 119, 668-672.
24. Panguluri, R.C. et al. (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis, 25, 961-966.
25. Slattery, M.L. et al. (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol. Biomarkers Prev., 16, 747-755.
26. Smith, K.C. et al. (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet., 31, 167-173.
27. Gonzalez-Zuloeta Ladd, A.M. et al. (2006) Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur. J. Epidemiol., 21, 373-376.
28. Skerrett, D.L. et al. (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest., 23, 208-214.
29. Hunter, D.J. et al. (2005) A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat. Rev. Cancer, 5, 977-985.
30. Calle, E.E. et al. (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer, 94, 2490-2501.
31. Riboli, E. et al. (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr., 5, 1113-1124.
32. Colditz, G.A. et al. (2005) The Nurses' Health Study: lifestyle and health among women. Nat. Rev. Cancer, 5, 388-396.
33. Rexrode, K.M. et al. (2000) Baseline characteristics of participants in the Women's Health Study. J. Womens Health Gend. Based Med., 9, 19-27.
34. Kolonel, L.N. et al. (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol., 151, 346-357.
35. Hayes, R.B. et al. (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin. Trials, 21, 349S-355S.
36. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 330, 1029-1035.
37. Giovannucci, E. et al. (2003) Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol. Biomarkers Prev., 12, 84-89.
38. Chan, J.M. et al. (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst., 94, 1099-1106.
39. Feigelson, H.S. et al. (2006) Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res., 66, 2468-2475.
40. Kraft, P. et al. (2005) Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet., 1, e68.
41. de Bakker, P.I. et al. (2005) Efficiency and power in genetic association studies. Nat. Genet., 37, 1217-1223.
42. Carlson, C.S. et al. (2004) Selecting a maximally informative set of singlenucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet., 74, 106-120.
43. Higgins, J.P. et al. (2002) Quantifying heterogeneity in a meta-analysis. Stat. Med., 21, 1539-1558.
44. Gao, X. et al. (2008) A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet. Epidemiol., 32, 361-369.
45. Cao, Y. et al. (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol., 190, 279-286.
46. Lee, S.H. et al. (2005) Cyclooxygenase-2-mediated DNA damage. J. Biol. Chem., 280, 28337-28346.
47. Blair, I.A. (2001) Lipid hydroperoxide-mediated DNA damage. Exp. Gerontol., 36, 1473-1481.
48. Fishman, D. et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest., 102, 1369-1376.
49. Iacopetta, B. et al. (2004) The -174 G/C gene polymorphism in interleukin6 is associated with an aggressive breast cancer phenotype. Br. J. Cancer, 90, 419-422.
50. Hefler, L.A. et al. (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin. Cancer Res., 11, 5718-5721.
51. Kesarwani, P. et al. (2008) Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol., 27, 505-510.
52. Michaud, D.S. et al. (2006) Genetic polymorphisms of interleukin-1B (IL1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res., 66, 4525-4530.
53. Sun, J. et al. (2004) Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., 13, 1677-1679.
54. Knupfer, H. et al. (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat., 102, 129-135.
55. Culig, Z. (2005) Interleukin-6 polymorphism: expression and pleiotropic regulation in human prostate cancer. J. Urol., 174, 417.